ELVN
NASDAQEnliven Therapeutics Inc.
News25/Ratings11
News · 26 weeks55+200%
2026-03-012026-08-23
Mix3690d
- SEC Filings13(36%)
- Insider11(31%)
- Other4(11%)
- Analyst3(8%)
- Offering3(8%)
- Earnings2(6%)
Latest news
25 items- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin sold $352,551 worth of shares (6,018 units at $58.58) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 40,036 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $292,931 worth of shares (5,000 units at $58.59) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- ANALYSTWilliam Blair initiated coverage on Enliven TherapeuticsWilliam Blair initiated coverage of Enliven Therapeutics with a rating of Outperform
- ANALYSTBarclays initiated coverage on Enliven Therapeutics with a new price targetBarclays initiated coverage of Enliven Therapeutics with a rating of Overweight and set a new price target of $78.00
- INSIDERDirector Derynck Mika K exercised 158,795 shares at a strike of $10.84 and sold $9,561,587 worth of shares (158,795 units at $60.21) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Enliven Therapeutics Inc.SCHEDULE 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 10-Q filed by Enliven Therapeutics Inc.10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAnnounced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profileReached alignment with the FDA on key Phase 3 trial design componentsStrong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030BURLINGAME, Calif., Aug. 5, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a busines
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin sold $316,780 worth of shares (6,018 units at $52.64) as part of a pre-agreed trading plan and exercised 1,072 shares at a strike of $2.48, decreasing direct ownership by 10% to 46,054 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $263,373 worth of shares (5,000 units at $52.67) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERDirector Kunkel Lori Anne sold $504,903 worth of shares (10,000 units at $50.49) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 41,884 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERLarge owner Orbimed Advisors Llc sold $39,014,046 worth of shares (860,123 units at $45.36) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Enliven Therapeutics Inc.SCHEDULE 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin exercised 6,018 shares at a strike of $2.48 and sold $263,577 worth of shares (6,018 units at $43.80) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise sold $219,017 worth of shares (5,000 units at $43.80) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERLarge owner Orbimed Advisors Llc sold $12,668,988 worth of shares (281,408 units at $45.02) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Enliven Therapeutics Inc.SCHEDULE 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- PREnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesBURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, wh
ELVN FAQ
6 questionsWhere does ELVN stock trade?
Enliven Therapeutics Inc. (ELVN) is listed on NASDAQ.What sector and industry is ELVN in?
Enliven Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enliven Therapeutics Inc. go public?
Enliven Therapeutics Inc. (ELVN) completed its IPO in 2020.What are analysts saying about ELVN?
Enliven Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-08-18. Recent price targets range from $3200.00 to $4200.00.What companies are similar to ELVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ELVN side-by-side with any of them on Quantisnow.How can I track ELVN on Quantisnow?
Quantisnow aggregates Enliven Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELVN to receive live email and push alerts on every new disclosure.